• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis
【24h】

Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis

机译：多发性硬化症和炎症性肠病疾病：系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The association between multiple sclerosis ( MS) and inflammatory bowel disease (IBD) has been suggested, apart from their common epidemiological and immunological patterns, also due to observations of increased incidence of both IBD among MS patients and MS among IBD patients. We estimated the risk of concurrent IBD and MS comorbidity, using data from all available case-control studies. We calculated the corresponding Risk ratios (RRs) in each included case-control study to express the risk of IBD and MS concurrence at a given population. We performed additional subgroup analyses according to the type of registry from which the data of the cases were exported ( IBD or MS registry) and the IBD type ( Crohn's disease, CD or Ulcerative colitis, UC). We included 10 studies, comprising a total of 1,086,430 patients ( 0.08% of them with concurrent IBD and MS). Pooled RR for IBD/ MS comorbitity was 1.54 ( 95% CI 1.40- 1.67; p<0.0001) with no differences ( p=0.91) among IBD and MS registries ( RR 1.53, 95% CI 1.36- 1.72, p<0.001 for MS comorbidity in IBD patients vs. RR 1.55, 95% CI 1.32- 1.81, p<0.001 for IBD comorbidity in MS patients). No difference was also found on the risk of MS comorbidity among patients with CD or UC ( RR 1.52, 95% CI 1.34- 1.72, p<0.001 vs. RR 1.55, 95% CI 1.38- 1.74, p<0.001; p for subgroup differences: 0.84). In all analyses no evidence of heterogeneity or publication bias was detected. Both IBD and MS patients seem to have a fifty-percent increased risk of MS or IBD comorbidity, respectively, with no apparent differences between patients with CD or UC.
机译：已经提出了多发性硬化症（MS）和炎性肠病（IBD）之间的关联，除了常见的流行病学和免疫模式，也是由于在IBD患者中MS患者和MS中的IBD中的发病率增加。我们估计了来自所有可用案例控制研究的数据的并发IBD和MS合并症的风险。我们计算了每个包括案例对照研究中的相应风险比（RRS），以表达IBD和MS并发在给定人群中的风险。我们根据进出口数据的类型（IBD或MS注册表）和IBD型（Crohn病，CD或溃疡性结肠炎，UC）进行了额外的子组分析。我们包括10项研究，总共包括1,086,430名患者（其中0.08％，同时IBD和MS）。用于IBD / MS混合性的汇总RR为1.54（95％CI 1.40- 1.67; P <0.0001），IBD和MS注册表中没有差异（P = 0.91）（RR 1.53,95％CI 1.36- 1.72，P <0.001对于MS。 IBD患者的合并症与RR 1.55,95％CI 1.32- 1.81，P <0.001用于MS患者的IBD合并症）。 CD或UC患者的MS合并症的风险没有差异（RR 1.52,95％CI 1.34- 1.72，P <0.001 Vs.RR 1.55,95％CI 1.38- 1.74，P <0.001; P用于子组差异：0.84）。在所有分析中，没有检测到异质性或出版物偏差的证据。 IBD和MS患者的患者似乎分别具有5％的风险，分别增加了MS或IBD合并症的风险，在CD或UC患者之间没有明显差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号